Target to treat a metabolic disease in an individual
AssigneeUniversidad Del Pais Vasco/Euskal Herriko Unibertsitatea
InventorsPatricia Aspichueta Celaá, Xabier Buqué García, Diego Sáenz de Urturi
Life of this patent
Estimating the term…
Abstract
Provided herein are methods, compounds, and compositions for reducing expression of MAT1a in a cell or individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a metabolic disease or disorder in an individual.
Claims11
A method of treating or ameliorating a metabolic disease or disorder in an individual having a metabolic disease or disorder comprising administering a MAT1a specific inhibitor to the individual, thereby treating or ameliorating the metabolic disease or disorder in the individual, wherein the metabolic disease or disorder is obesity, diabetes, insulin resistance, or dyslipidemia, and wherein the MAT1a specific inhibitor is a nucleic acid comprising a modified oligonucleotide targeting MAT1a comprising:
- a gap segment consisting of linked deoxynucleosides;
- a 5′ wing segment consisting of linked nucleosides;
- a 3′ wing segment consisting of linked nucleosides;
- wherein the gap segment is positioned immediately adjacent to and between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar;
- and wherein the modified oligonucleotide is selected from the group consisting of SEQ ID NO:
- 17, SEQ ID NO:
- 18, SEQ ID NO:
- 83, SEQ ID NO:
- 84, SEQ ID NO:
- 159 and SEQ ID NO:
- 216.
A method of inhibiting expression or activity of MAT1a in a cell comprising contacting the cell with a MAT1a specific inhibitor, thereby inhibiting expression or activity of MAT1a in the cell, wherein the cell is a hepatocyte from an individual having obesity, diabetes, insulin resistance, or dyslipidemia, and wherein the MAT1a specific inhibitor is a nucleic acid comprising a modified oligonucleotide targeting MAT1a comprising
- a gap segment consisting of linked deoxynucleosides;
- a 5′ wing segment consisting of linked nucleosides;
- a 3′ wing segment consisting of linked nucleosides;
- wherein the gap segment is positioned immediately adjacent to and between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar;
- and wherein the modified oligonucleotide is selected from the group consisting of SEQ ID NO:
- 17, SEQ ID NO:
- 18, SEQ ID NO:
- 83, SEQ ID NO:
- 84, SEQ ID NO:
- 159 and SEQ ID NO:
- 216.
Dependencies are inferred from the claim text.